Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study.

A Fagotti¹, J-S Frenel², M Saint-Ghislain³, J T Lim⁴, T A Calderón Boyle⁴, A K Golembesky⁵, C Hogg⁶, K Arnold⁶, E I Braicu⁷

¹Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

²Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.

³Department of Medical Oncology, Institut Curie, Paris, France.

⁴GSK, Upper Providence, Pennsylvania, USA.

⁵GSK, Durham, North Carolina, USA.

⁶IQVIA, London, UK.

⁷Department for Gynecology, Charite Universitätsmedizin, Berlin, Germany.

PubMed PMC DOI PDF

Abstract

BACKGROUND: In this real-world study, outcomes were evaluated in patients with stage III advanced epithelial ovarian cancer (EOC) with no visible residual disease (NVRD) after primary cytoreductive surgery (PCS), a subgroup excluded from the phase III PRIMA trial. MATERIALS AND METHODS: The noninterventional, retrospective EUROPA study included patients with advanced (stage III or IV) EOC who ini…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.